Ultomiris Secures US Accelerated Approval in IgA Nephropathy, Its Fifth Indication
AZN is trading near its 52-week low of $153.413 (10.0% above the low).
Summary
Ultomiris, AstraZeneca's complement inhibitor, has received US accelerated approval to reduce proteinuria in adults with IgA nephropathy — its fifth indication — on the strength of a 43.4% placebo-adjusted proteinuria reduction at week 34. Full approval still depends on the ongoing I CAN trial confirming a kidney-function benefit.
Updates
· Benzinga — AstraZeneca shares rose 2.49% to $172.65 following the Ultomiris accelerated approval.
- Proteinuria reduction appeared as early as week 10: 36.7% drop versus 8.5% for placebo
- Efficacy consistent across patient subgroups regardless of demographics or baseline disease severity
- Qualified adults receive intravenous infusion every eight weeks after weight-based loading dose
Key Events · Product Development and Regulatory · AZN
-
Ultomiris Approved in IgAN
The US FDA granted accelerated approval to Ultomiris (ravulizumab) for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression — the first and only C5 complement inhibitor approved for this use.
-
43.4% Proteinuria Reduction
In the prespecified interim analysis of I CAN, Ultomiris reduced 24-hour UPCR by 46.6% from baseline at week 34, versus 5.6% for placebo — a placebo-adjusted effect of 43.4% (95% CI 33.5%-51.8%; p<0.0001).
-
Accelerated Approval Conditions
Continued approval may be contingent on verifying clinical benefit in the ongoing I CAN Phase III trial, which assesses change in eGFR at week 106 for traditional approval; whether Ultomiris slows kidney function decline has not been established.
-
Fifth Indication, Global Filings
This is Ultomiris's fifth indication and follows Priority Review; regulatory submissions based on the interim results are also under review in Japan and additional countries.
Analysis · AZN · Life Sciences
Ultomiris is now the first and only C5 complement inhibitor approved in the US to reduce proteinuria in adults with primary IgA nephropathy, a rare kidney disease that affects more than 200,000 people in the US. The label rests on a 43.4% placebo-adjusted reduction in proteinuria at week 34 from the interim analysis of the I CAN Phase III trial, and it adds a fifth indication to Alexion's franchise. The caveat: this is accelerated approval, so continued marketing depends on the ongoing trial confirming a benefit on kidney function (eGFR at week 106) — commercial value therefore hinges on a readout that has not yet occurred. Near-term revenue is incremental rather than transformative for a company of AstraZeneca's size, but the approval extends the rare-disease growth story and opens filings in Japan and other markets.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.3% of the 1529 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $168.70 on NYSE in the Life Sciences sector, with a market capitalization of approximately $261.3B. The 52-week trading range was $153.41 to $212.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.